Pharma channel feed – Endpoints News

Pharma channel feed

Reshaping Novartis into a more aggressive pharma giant, Vas Narasimhan bags a $13B consumer sale ahead of bolt-on deals

8 years ago

Congress approves government spending bill with increased FDA funding

8 years ago

In a blow to its biggest revenue driver, Indivior loses patent battle with generics maker Alvogen

8 years ago

Sun Pharma screeches to the psoriasis finish line with FDA OK of Ilumya. Too bad rivals J&J and others beat them to it

8 years ago

House Republicans mount a successful comeback campaign for right-to-try bill

8 years ago

NYC's biotech scene gets cash and office space with Beacon's new incubator

8 years ago

Celgene goes all-out on neurodegeneration and Alzheimer’s, triggering blockbuster deal with $150M in cash for Prothena

8 years ago

FDA hands Seattle Genetics its 5th OK for Adcetris. But can they actually sell it for frontline Hodgkin lymphoma?

8 years ago

Sahm Adrangi’s Kerrisdale knifes Proteostasis’ 'breakthrough' cystic fibrosis data in a brutal biotech short attack

8 years ago

Donald Trump promises (again) to slash drug prices substantially; 'and it’s going to be beautiful’

8 years ago

FDA OKs Hizentra for rare autoimmune disease CIDP

8 years ago

Dems, Republicans split on 340B drug pricing program in Senate hearing

8 years ago

China stocks the new trend? Loncar launches index

8 years ago

Swapping stock and cash, Ionis turns to closely-controlled Akcea for a deal on spurned drug inotersen

8 years ago

FDA slaps a hold on Solid Bio's gene therapy for Duchenne MD in wake of safety alert

8 years ago

Lousy year for shareholders, but Allergan CEO Brent Saunders sprints past Gorsky, Gonzalez with $32M pay package

8 years ago

'Right-to-try' bill fails to muster votes, dies in the House (for now)

8 years ago

Teva calls off CGRP drug discovery and development pact, returns preclinical asset to Sosei

8 years ago

Proteostasis stock soars on cystic fibrosis breakthrough status

8 years ago

Busy Sanofi takes a pass on one of Alnylam’s rare disease drugs, FDA offers ‘breakthrough’ status for PhIII

8 years ago

Biogen is hustling a schizophrenia drug into PhIIb after Pfizer lets it go in $590M CNS fire sale

8 years ago

Regeneron boosted, rival Esperion slammed as investors scramble to catch up to a PCSK9 price war

8 years ago

Praluent Odyssey: Regeneron/Sanofi gun for market breakout with first-ever mortality benefit — and a big price discount

8 years ago

Senators heap abuse on Allergan's attempt at an end run around patent reviews, offer bill to stop 'sham'

8 years ago

First page Previous page 301 302 303304305 306 307 Next page Last page